Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Longeveron Inc. (LGVN : NSDQ)
 
 • Company Description   
Longeveron Inc. is a clinical stage biotechnology company. It engages in developing cellular therapies for chronic aging-related and life-threatening conditions. The company's investigational product includes LOMECEL-B(TM). Longeveron Inc. is based in MIAMI.

Number of Employees: 12

 
 • Price / Volume Information   
Yesterday's Closing Price: $20.12 Daily Weekly Monthly
20 Day Moving Average: 34,601,340 shares
Shares Outstanding: 19.12 (millions)
Market Capitalization: $384.71 (millions)
Beta:
52 Week High: $45.00
52 Week Low: $2.84
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 372.30% 387.04%
12 Week 415.90% 410.76%
Year To Date % %
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
1951 NW 7TH AVENUE SUITE 520
-
MIAMI,FL 33136
USA
ph: 305-909-0840
fax: -
investorrelations@longeveron.com http://www.longeveron.com
 
 • General Corporate Information   
Officers
Geoff Green - Chief Executive Officer
Joshua M. Hare - Chairman and Director
James Clavijo - Chief Financial Officer and Treasurer
Paul Lehr - Secretary
Donald M. Soffer - Director

Peer Information
Longeveron Inc. (CORR.)
Longeveron Inc. (RSPI)
Longeveron Inc. (CGXP)
Longeveron Inc. (BGEN)
Longeveron Inc. (GTBP)
Longeveron Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 54303L104
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 09/01/21
Next Expected EPS Date: 02/11/22
Share - Related Items
Shares Outstanding: 19.12
Most Recent Split Date: (:1)
Beta:
Market Capitalization: $384.71 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 02/11/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 17.23
Price/Cash Flow: -
Price / Sales: 168.88
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: 3.85%
Sales Growth
vs. Year Ago Period: -87.56%
vs. Previous Quarter: -52.56%
ROE
09/30/21 - -75.99
06/30/21 - -78.44
03/31/21 - -93.06
ROA
09/30/21 - -58.09
06/30/21 - -58.23
03/31/21 - -63.53
Current Ratio
09/30/21 - 10.18
06/30/21 - 10.12
03/31/21 - 9.10
Quick Ratio
09/30/21 - 10.18
06/30/21 - 10.12
03/31/21 - 9.10
Operating Margin
09/30/21 - -629.06
06/30/21 - -266.25
03/31/21 - -154.00
Net Margin
09/30/21 - -629.06
06/30/21 - -266.25
03/31/21 - -154.00
Pre-Tax Margin
09/30/21 - -629.06
06/30/21 - -266.25
03/31/21 - -154.00
Book Value
09/30/21 - 1.17
06/30/21 - 1.29
03/31/21 - 1.40
Inventory Turnover
09/30/21 - -
06/30/21 - -
03/31/21 - -
Debt-to-Equity
09/30/21 - 0.01
06/30/21 - 0.01
03/31/21 - 0.01
Debt-to-Capital
09/30/21 - 0.64
06/30/21 - 0.58
03/31/21 - 0.55
 

Powered by Zacks Investment Research ©